Let’s hear it for Lily Orn, named our Commercial team’s 2024 Master Ambassador. Her strong cross-functional partnerships and leadership in the member growth marketing team are crucial for the team’s success. Thanks for all you do, Lily! 🧡
An exceptional leader with a steadfast dedication to her team, we’d like to congratulate the Commercial Team Manager of 2024, Julia DiMartinis. Thank you for what you do, Julia! We appreciate you. 🧡
It’s awards season and we’d like to honor the amazing Omada Commercial team members! With exceptional performance in supporting and empowering our customers and delivering results, the Commercial team’s Partner Powerhouse for 2024 is Beth (Riphagen) Goodwin! Thank you for embodying Omada’s values, Beth! 👏
🥁 And the Commercial Omadan of the Year goes to … Michelle Percia! She stands out from the crowd in her dedication and thoughtfulness. Her involvement in so many initiatives and an ability to connect the dots, ask thoughtful questions, and take initiatives from idea to completion in a blink of an eye is always impressive. Let’s hear a round of applause for Michelle! 👏
A big shout out to Dane Woodley! As the master of analogies, the king of creativity, and the tr-AI-lblazer of productivity, he is the Commercial team’s 2024 Most Valuable Supporter. We’re so lucky to have you, Dane! 🙏
A team player across functions, a great attitude, and a calm in the chaos, Bhupendra Patel is our Commercial team’s 2024 Foundation Builder. Let’s give a round of applause for all he’s done to help his team, and Omada, succeed! Thank you 👏
🚨 Omada Health released findings from a survey of 1,000 consumers using GLP-1s for weight loss. Key highlights include: 🔍 Only 18% of those who discontinued GLP-1s achieved their weight loss goals, indicating unmet needs in long-term support. 💸 Access and cost challenges significantly impact medication persistence, with many facing barriers to continued use. These insights emphasize the importance of support beyond medication. Learn more about our findings: https://lnkd.in/eUY3Z5EY
🚨Exciting news from our clinical team! 🚨 We have findings from a qualitative study in collaboration with Stanford Healthcare AI Applied Research Team (HEA3RT). The study explored a topic we know customers and partners care a lot about … integrating primary and virtual care. By teaming up with healthcare providers, we're digging into the potential, challenges, and possibilities of virtual care. Check out a recent Proof Points to learn more about our findings: https://lnkd.in/eRa_6BHy
🚨New Analysis on GLP-1 Discontinuation from Omada Health🚨 A new real-world analysis shows that Omada members, on average, experienced virtually no weight gain 16 weeks after discontinuing a GLP-1 compared to an average of 6-7% weight gain estimated from trial data. Carolyn Bradner Jasik, MD states, “These findings show that members who are better supported throughout their journey can be more successful post-discontinuation when GLP-1s are paired with lifestyle change programs like Omada.” Learn more: https://lnkd.in/dviYtTUa
💡Did you know that 76 % of Omada for Diabetes members have met our A1C reduction goals in the program? 💡 Through proactive support and science-backed intervention, Omada can close gaps in care to help members manage their diabetes for improved long-term results. Want to learn more about the Omada for Diabetes program? Check it out: https://lnkd.in/eHT7m6vi
